Obesity Therapeutics to 2019 – Safety Concerns Hinder Drug Performance Despite Large Market Opportunity...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Etiology and Pathophysiology 9
2.2 Classification 9
2.3 Epidemiology 10
2.3.1 The US 10
2.3.2 Obesity in the Top Five European Markets 10
2.3.3 Japan 10
2.4 Comorbidities 11
2.4.1 Type 2 Diabetes 11
2.4.2 Hypertension 11
2.4.3 Dyslipidemia 11
2.4.4 Respiratory Problems 12
2.4.5 Osteoarthritis 12
2.4.6 Cancer Risk 12
2.5 Economic Burden 12
2.6 Current Therapy Options 12
2.6.1 Lifestyle and Behavioral Modifications 12
2.6.2 Bariatric Surgery 13
2.6.3 Pharmacotherapy 13
2.6.4 Treatment Algorithms and Prescription Habits 15
2.6.5 Method of Determining Treatment Effectiveness 16
2.7 Why Develop Therapeutic Anti-obesity Drugs? 16
3 Marketed Products 18
3.1 Amphetamine-like Drugs 18
3.1.1 Overview 18
3.1.2 Efficacy Profile 19
3.1.3 Safety Profile 19
3.2 Qsymia, Vivus, Inc. 19
3.2.1 Overview 19
3.2.2 Efficacy Profile 20
3.2.3 Safety Profile 21
3.2.4 Discussion 22
3.3 Orlistat 22
3.3.1 Overview 22
3.3.2 Efficacy Profile 23
3.3.3 Safety Profile 25
3.3.4 Discussion 25
3.4 Belviq, Arena Pharmaceuticals 26
3.4.1 Introduction 26
3.4.2 Efficacy Profile 26
3.4.3 Safety Profile 27
3.4.4 Discussion 27
3.5 Low Long-term Success Rate of Marketed Anti-Obesity Drugs 28
3.6 Discussion 29
4 Pipeline 33
4.1 Overview of Pipeline by Phase, Molecule Type and Molecular Target 33
4.2 Clinical Trial Duration and Size 36
4.2.1 Clinical Trial Duration 36
4.2.2 Clinical Trial Size 38
4.3 Clinical Trial Failure, Attrition Rate and Reasons for Clinical Trial Failure 39
4.4 Primary and Secondary Endpoints 41
4.5 Late-stage Drugs of the Developmental Pipeline 43
4.5.1 Contrave, Orexigen Therapeutics 43
4.5.2 Cametor, Norgine BV 45
4.5.3 Victoza, Novo Nordisk 47
4.5.4 Tesofensine (NeuroSearch) 50
4.6 Discussion 51
5 Market Forecasts 54
5.1 Global Market 54
5.2 The US 56
5.2.1 Epidemiology and Treatment Usage Patterns 56
5.2.2 Annual Cost of Therapy 56
5.2.3 Market Size 56
5.3 Europe 58
5.3.1 Treatment Usage Patterns 58
5.3.2 Annual Cost of Therapy 60
5.3.3 Market Size 61
5.4 Japan 63
5.4.1 Treatment Usage Patterns 63
5.4.2 Annual Cost of Therapy 63
5.4.3 Market Forecast 63
5.5 Discussion 64
5.6 Drivers and Barriers of the Anti-obesity Market 65
5.7 Obesity Market Drivers 65
5.7.1 Obesity is a Very Prevalent Disease with Large Potential Target Populations Globally 65
5.7.2 Recent Approval of Qsymia to Drive Market Growth Providing its Long-term Safety is Proved 65
5.7.3 Diversification of Molecular Targets 65
5.8 Obesity Market Barriers 66
5.8.1 Low Treatment Rate 66
5.8.2 Reimbursement Issues 66
6 Licensing and Co-Development Deals 67
6.1 Licensing Deals 67
6.1.1 EMD Serono Enters into Collaboration and Licensing Agreement with Theratechnologies 68
6.1.2 Amylin Pharma Enters into Licensing Agreement with Takeda Pharma 68
6.1.3 Palatin Technologies Extends License Agreement with AstraZeneca 69
6.1.4 Zealand Pharma Enters into Licensing and Collaboration Agreement with Boehringer Ingelheim 69
6.2 Co-development Deals 70
6.2.1 Isis Enters into Collaboration Agreement with Ortho-McNeil 71
6.2.2 Orexigen Therapeutics Enters into Co-development Agreement with Takeda Pharma for Contrave 71
7 Appendix 72
7.1 References 72
7.2 Abbreviations 76
7.3 All Pipeline Drugs by Phase 79
7.3.1 Discovery 79
7.3.2 Preclinical 80
7.3.3 Phase I 84
7.3.4 Phase II 85
7.3.5 Phase III 86
7.3.6 Pre-Registration 86
7.4 Market Forecasts to 2019 87
7.4.1 Global 87
7.4.2 The US 87
7.4.3 UK 88
7.4.4 France 88
7.4.5 Germany 88
7.4.6 Italy 89
7.4.7 Spain 89
7.4.8 Japan 89
7.5 Methodology 90
7.6 Secondary Research 90
7.7 Therapeutic Landscape 90
7.8 Epidemiology-Based Forecasting 91
7.9 Market Size by Geography 92
7.10 Pipeline Analysis 93
7.11 Contact Us 93
7.12 Disclaimer 93